![]()
侯旭奔
-
副教授
博士生导师
硕士生导师
- 性别：男
- 出生日期：1990-03-22
- 毕业院校：山东大学
- 学历：研究生(博士后)
- 学位：医学博士学位
- 在职信息：在职
- 所在单位：药学院
- 入职时间： 2018-12-18
- 学科：药物化学
- 办公地点：趵突泉校区景蓝斋
大学科技园3号楼1514室
- 电子邮箱：houxuben@163.com
访问量：
-
[21]
.
Structural insight into TIPE1 functioning as a lipid transfer protein.
JOURNAL OF BIOMOLECULAR STRUCTURE AND DYNAMICS,
2023.
-
[22]
Liang, Xiao.
Design, synthesis and biological evaluation of hydantoin derivatives as Mcl-1 selective inhibitors.
Bioorganic Chemistry,
121,
105643,
2022.
-
[23]
侯旭奔.
Discovery of Novel Src Homology-2 Domain-Containing Phosphatase 2 and Histone Deacetylase Dual Inhib.
Journal of Medicinal Chemistry,
2022.
-
[24]
侯旭奔.
PTPRO is a therapeutic target and correlated with immune infiltrates in pancreatic cancer.
Journal of Cancer,
12,
7445-7453,
2021.
-
[25]
梁翰之.
Structure-Based Design of 2-Aminopurine Derivatives as CDK2 Inhibitors for Triple-Negative Breast Ca.
FRONT PHARMACOL,
13,
864342,
2022.
-
[26]
陈晨.
Discovery of DNA-Targeting HDAC Inhibitors with Potent Antitumor Efficacy In Vivo That Trigger Antit.
Journal of Medicinal Chemistry,
65,
3667,
2022.
-
[27]
刘蒙.
Strategies to overcome drug resistance using SHP2 inhibitors.
ACTA PHARMACEUTICA SINICA B,
11,
3908,
2021.
-
[28]
刘璐璐.
Design, synthesis and biological evaluation of tyrosine derivatives as Mcl-1 inhibitors.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,
191,
2020.
-
[29]
孙金鹏 , 方浩 and 侯旭奔.
Inhibition of striatal-enriched protein tyrosine phosphatase by targeting computationally revealed c.
EUR J MED CHEM,
190,
2020.
-
[30]
杜金童.
Structure-based virtual screening, biological evaluation and biophysical study of novel Mcl-1 inhibi.
Future Medicinal Chemistry,
12,
1293,
2020.
-
[31]
梁涛.
Design, synthesis and biological evaluation of 3, 4-disubstituted-imidazolidine-2, 5-dione derivativ.
European Journal of Medicinal Chemistry,
221,
2021.
-
[32]
李雯.
Photopharmacology-based small-molecule proteolysis targeting chimeras: optical control of protein de.
Future Medicinal Chemistry,
12,
1991,
2020.
-
[33]
Reham M Elhassan.
Recent advances in the development of allosteric protein tyrosine phosphatase inhibitors for drug di.
Medicinal Research Reviews,
42,
1064,
2022.
-
[34]
郭永真.
Recent Applications of Benzimidazole as a Privileged Scaffold in Drug Discovery.
Mini-Reviews in Medicinal Chemistry,
21,
1367,
2021.
-
[35]
李雯.
Recent Advances in Small Molecule PROTACs for the Treatment of Cancer.
Current Medicinal Chemistry,
28,
4893,
2021.
-
[36]
赵雲鹏.
Recent Development of Novel HDAC6 Isoform-selective Inhibitors.
Current Medicinal Chemistry,
28,
4133,
2021.
-
[37]
范颖.
Recent Advances in the Development of Selective Mcl-1 Inhibitors for the Treatment of Cancer (2017-P.
Recent Patents on Anti-Cancer Drug Discovery,
15,
306,
2020.
-
[38]
梁翰之.
Recent progress in development of cyclin-dependent kinase 7 inhibitors for cancer therapy.
EXPERT OPINION ON INVESTIGATIONAL DRUGS,
30,
61,
2021.
-
[39]
Zhao, Jing.
Substrate interaction inhibits gamma-secretase production of amyloid-beta peptides.
chemical communications,
56,
2578,
2020.
-
[40]
杜金童.
An in silico mechanistic insight into HDAC8 activation facilitates the discovery of new small-molecu.
BIOORGANIC & MEDICINAL CHEMISTRY Journal,
28,
2020.
